| Literature DB >> 30286762 |
Yi Hou1, Xudong Wang1, Jing Chen2.
Abstract
BACKGROUND: To demonstrate the prognostic significance and value of lymph node ratio (LNR) and evaluate the possibility of becoming a new indicator to enhance the current Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) tumor, lymph node, metastasis (TNM) staging system.Entities:
Keywords: Gastric cancer; Lymph node ratio; Multivariate analysis; Prognosis; Survival analysis
Mesh:
Year: 2018 PMID: 30286762 PMCID: PMC6172727 DOI: 10.1186/s12957-018-1504-5
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Clinical and histopathology data of all 221 patients
| Variables | Number of patients | Percent (%) |
|---|---|---|
| Sex | ||
| Male | 160 | 72.4 |
| Female | 61 | 27.6 |
| Age (years) | ||
| ≥ 65 | 100 | 45.2 |
| < 65 | 121 | 54.8 |
| Grade | ||
| Well or moderately differentiated | 51 | 23.1 |
| Poorly differentiated | 170 | 76.9 |
| Location | ||
| Lower | 180 | 81.4 |
| Middle | 13 | 5.9 |
| Upper | 28 | 12.7 |
| T stage | ||
| T1 | 23 | 10.4 |
| T2 | 39 | 17.6 |
| T3 | 98 | 44.3 |
| T4 | 61 | 27.6 |
| N stage | ||
| N0 | 67 | 30.3 |
| N1 | 46 | 20.8 |
| N2 | 34 | 15.4 |
| N3 | 74 | 33.5 |
| TNM stage | ||
| I | 43 | 19.5 |
| II | 63 | 28.5 |
| III | 115 | 52.0 |
| LN | ||
| < 15 | 43 | 19.5 |
| ≥ 15 | 178 | 80.5 |
| LNR | ||
| 0 | 68 | 30.8 |
| 0–0.13 | 47 | 21.3 |
| 0.13–0.4 | 54 | 24.4 |
| > 0.4 | 52 | 23.5 |
The depth of primary tumor invasion (T stage), classification of regional metastasis lymph nodes (N stage), and TNM stage were based on the 7th edition TNM staging system; LN: number of lymph nodes examined; LNR: ratio between the positive lymph nodes and the total number of lymph nodes examined
Fig. 1The factors with statistical significance of univariate analysis and panels a to e reveal the survival curves of grade, T stage, N stage, TNM stage, and LNR, respectively
Univariate Analysis of 221 Patients with curative gastrectomy
| Variables | Median survival (month) | |
|---|---|---|
| Sex | 0.824 | |
| Male | 44.0 | |
| Female | 41.0 | |
| Age (years) | 0.482 | |
| ≥ 65 | 41.0 | |
| < 65 | 42.0 | |
| Grade | < 0.001 | |
| Well or moderately differentiated | 61.0 | |
| Poorly differentiated | 36.0 | |
| Location | 0.405 | |
| Lower | 40.5 | |
| Middle | 45.0 | |
| Upper | 50.0 | |
| T stage | < 0.001 | |
| T1 | 64.0 | |
| T2 | 59.0 | |
| T3 | 41.5 | |
| T4 | 25.0 | |
| N stage | < 0.001 | |
| N0 | 60.0 | |
| N1 | 47.0 | |
| N2 | 31.0 | |
| N3 | 18.5 | |
| TNM stage | < 0.001 | |
| I | 62.0 | |
| II | 47.0 | |
| III | 26.0 | |
| LN | 0.895 | |
| < 15 | 44.0 | |
| ≥ 15 | 41.5 | |
| LNR | < 0.001 | |
| 0 | 60.0 | |
| 0–0.13 | 47.0 | |
| 0.13–0.4 | 35.5 | |
| > 0.4 | 17.0 | |
The depth of primary tumor invasion (T stage), classification of regional metastasis lymph nodes (N stage) and TNM stage were based on the 7th edition TNM staging system; LN: number of lymph nodes examined; LNR: ratio between the positive lymph nodes and the total number of lymph nodes examined
Multivariable analysis of all Variables using Cox proportional hazard regression model
| Variables | HR | 95.0% CI | ||
|---|---|---|---|---|
| Lower | Upper | |||
| Grade | ||||
| Well or moderately differentiated | 1 | |||
| Poorly differentiated | 0.442 | < 0.001 | 0.284 | 0.689 |
| T stage | ||||
| T1 | 1 | |||
| T2 | 0.086 | < 0.001 | 0.033 | 0.228 |
| T3 | 0.225 | < 0.001 | 0.128 | 0.395 |
| T4 | 0.277 | < 0.001 | 0.189 | 0.407 |
| N stage | ||||
| N0 | 1 | |||
| N1 | 0.066 | 0.009 | 0.009 | 0.507 |
| N2 | 0.341 | 0.002 | 0.172 | 0.674 |
| N3 | 0.580 | 0.036 | 0.348 | 0.965 |
| LNR | ||||
| 0 | 1 | |||
| 0–0.13 | 2.358 | 0.402 | 0.317 | 17.519 |
| 0.13–0.4 | 0.721 | 0.342 | 0.368 | 1.414 |
| > 0.4 | 0.427 | < 0.001 | 0.277 | 0.659 |
CI: confidence interval
Fig. 2The survival curves of LNR in group 1 (LN ≥ 15) and group 2 (LN < 15), respectively. Panels a and b reveal the survival curves of LNR in group 1 (LN ≥ 15) and LNR in group 2 (LN < 15), respectively
Univariate analysis of LNR in groups with ≥ 15 and < 15 lymph nodes examined
| Number of patients | Percent (%) | Median survival (month) | ||
|---|---|---|---|---|
| Group 1 | ||||
| LNR | < 0.001 | |||
| 0 | 57 | 32.0 | 60.0 | |
| 0–0.13 | 38 | 21.3 | 47.0 | |
| 0.13–0.4 | 45 | 25.3 | 35.0 | |
| > 0.4 | 38 | 21.3 | 14.0 | |
| Group 2 | ||||
| LNR | < 0.001 | |||
| 0 | 11 | 25.6 | 60.0 | |
| 0–0.13 | 9 | 20.9 | 46.0 | |
| 0.13–0.4 | 9 | 20.9 | 39.0 | |
| > 0.4 | 14 | 32.6 | 20.5 | |
Comparisons of overall survival between R0 and R1, R2, or R3
| Median survival (month) | Chi-square | ||
|---|---|---|---|
| R1 | 47.0 | 6.999 | 0.008 |
| R2 | 35.5 | 28.101 | < 0.001 |
| R3 | 17.0 | 82.490 | < 0.001 |
Fig. 3The survival curves of LNR in group 2 (LN < 15) with the new cut-off